Research & Evidence | Adaptive Radiotherapy | 5D Cancer Services

Key Clinical Trials

Brain

Trial	NCT ID	Sponsor	Key outcomes
UNITED	NCT03713385	ViewRay	Demonstrated feasibility of MR-guided adaptive SBRT for brain metastases; supported sub-millimetre targeting accuracy.
UNITED-3	NCT04172753	ViewRay	Ongoing phase III; evaluates adaptive MR-guided radiosurgery vs. standard SRS for brain metastases.

Gynecologic

Trial	NCT ID	Sponsor	Key outcomes
EMBRACE I	NCT00432172	GEC-ESTRO	MRI-guided adaptive brachytherapy showed substantially improved local control and reduced morbidity in cervical cancer vs. historical controls.
EMBRACE II	NCT02247414	GEC-ESTRO	Prospective cohort confirming dose-volume parameter goals; ongoing refinement of adaptive brachytherapy protocols.

Head & Neck

Trial	NCT ID	Sponsor	Key outcomes
MSK Adaptive H&N Study	NCT03096808	Memorial Sloan Kettering	Adaptive re-planning reduced dose to parotid glands and spinal cord as anatomy changed during treatment, preserving salivary function.

Liver

Trial	NCT ID	Sponsor	Key outcomes
MR-guided Liver SBRT	NCT02683200	University of Colorado	Online adaptive MR-guided SBRT enabled safe dose escalation to liver tumors with real-time organ-at-risk tracking.

Multi-cancer

Trial	NCT ID	Sponsor	Key outcomes
MOMENTUM	NCT04075305	ViewRay (multi-institution)	Registry study across tumour types demonstrating MR-Linac-based adaptive radiotherapy is safe and deliverable at scale.

Pancreas

Trial	NCT ID	Sponsor	Key outcomes
SMART	NCT02621229	University of California San Diego	MR-guided adaptive SBRT (5 fractions) achieved high rates of local control in pancreatic cancer with low rates of severe GI toxicity.

Prostate

Trial	NCT ID	Sponsor	Key outcomes
HERMES	NCT04172923	Centre Léon Bérard	Phase II; evaluates MR-guided adaptive SBRT (5 fractions) for localised prostate cancer with daily on-table adaptation.
DESTINATION 2	NCT04272489	Erasmus MC	Assesses adaptive MR-Linac SBRT for prostate cancer, focusing on toxicity reduction through daily plan adaptation.
ASPIRE	NCT03815019	Sunnybrook Health Sciences	Prospective registry evaluating clinical outcomes of MR-guided adaptive radiotherapy for prostate and other cancers.

Rectal

Trial	NCT ID	Sponsor	Key outcomes
MARS	NCT04246684	MR-Linac Consortium	Investigates online adaptive MR-guided radiotherapy for rectal cancer as a route to organ preservation (watch-and-wait).
Adaptive Boost Trial	NCT03158077	University Medical Centre Utrecht	Adaptive simultaneous integrated boost in rectal cancer; assessed tumour response and normal-tissue sparing.